245 related articles for article (PubMed ID: 33651108)
1. Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs.
Herbrand AK; Schmitt AM; Briel M; Ewald H; Goldkuhle M; Diem S; Hoogkamer A; Joerger M; Moffa G; Novak U; Hemkens LG; Kasenda B
JAMA Netw Open; 2021 Mar; 4(3):e210380. PubMed ID: 33651108
[TBL] [Abstract][Full Text] [Related]
2. Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project.
Herbrand AK; Schmitt AM; Briel M; Diem S; Ewald H; Hoogkamer A; Joerger M; Mc Cord KA; Novak U; Sricharoenchai S; Hemkens LG; Kasenda B
ESMO Open; 2019; 4(6):e000596. PubMed ID: 31803503
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada.
Meyers DE; Jenei K; Chisamore TM; Gyawali B
JAMA Intern Med; 2021 Apr; 181(4):499-508. PubMed ID: 33616606
[TBL] [Abstract][Full Text] [Related]
4. Overall Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021.
Michaeli DT; Michaeli T
J Clin Oncol; 2022 Dec; 40(35):4095-4106. PubMed ID: 35921606
[TBL] [Abstract][Full Text] [Related]
5. Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy.
Trotta F; Mayer F; Barone-Adesi F; Esposito I; Punreddy R; Da Cas R; Traversa G; Perrone F; Martini N; Gyawali B; Addis A
BMJ Open; 2019 Dec; 9(12):e033728. PubMed ID: 31826897
[TBL] [Abstract][Full Text] [Related]
6. A Survey of Survival Outcomes for Targeted Cancer Drugs Approved by the US Food and Drug Administration.
He Q; Li Q; Lv F; Kaitin KI; Shao L
Ther Innov Regul Sci; 2021 Jul; 55(4):676-684. PubMed ID: 33683659
[TBL] [Abstract][Full Text] [Related]
7. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
[TBL] [Abstract][Full Text] [Related]
8. Access to anticancer drugs: many evidence-based treatments are off-label and unfunded by the Pharmaceutical Benefits Scheme.
Mellor JD; Van Koeverden P; Yip SW; Thakerar A; Kirsa SW; Michael M
Intern Med J; 2012 Nov; 42(11):1224-9. PubMed ID: 22372936
[TBL] [Abstract][Full Text] [Related]
9. Breakthrough Therapy Cancer Drugs and Indications With FDA Approval: Development Time, Innovation, Trials, Clinical Benefit, Epidemiology, and Price.
Michaeli DT; Michaeli T
J Natl Compr Canc Netw; 2024 Apr; 22(4):. PubMed ID: 38648855
[TBL] [Abstract][Full Text] [Related]
10. A uniform procedure for reimbursing the off-label use of antineoplastic drugs according to the value-for-money approach.
Messori A; Fadda V; Trippoli S
J Chemother; 2011 Apr; 23(2):67-70. PubMed ID: 21571620
[TBL] [Abstract][Full Text] [Related]
11. Correlation between clinical trial endpoints of marketed cancer drugs and reimbursement decisions in China.
Ling K; Qin H; Feng Y; Che H; Ding J; Li W
Front Public Health; 2022; 10():1062736. PubMed ID: 36504948
[TBL] [Abstract][Full Text] [Related]
12. Assessing cancer drugs for reimbursement: methodology, relationship between effect size and medical need.
de Sahb-Berkovitch R; Woronoff-Lemsi MC; Molimard M;
Therapie; 2010; 65(4):373-7, 367-72. PubMed ID: 20854761
[TBL] [Abstract][Full Text] [Related]
13. Reimbursement policies constrain the practice of oncology.
Laetz T; Silberman G
JAMA; 1991 Dec; 266(21):2996-9. PubMed ID: 1820471
[TBL] [Abstract][Full Text] [Related]
14. Use and reimbursement of off-label drugs in pediatric anesthesia: the Italian experience.
Salvo I; Landoni G; Mucchetti M; Cabrini L; Pani L
Paediatr Anaesth; 2014 Jun; 24(6):625-31. PubMed ID: 24796404
[TBL] [Abstract][Full Text] [Related]
15. Out-of-Pocket Spending Not Associated with Oral Oncolytic Survival Benefit.
Rotenstein LS; Dusetzina SB; Keating NL
J Manag Care Spec Pharm; 2018 Jun; 24(6):494-502. PubMed ID: 29799324
[TBL] [Abstract][Full Text] [Related]
16. Descriptive review and analysis of immunoglobulin utilization management from 2,548 prior authorization requests.
Tonkovic B; Rutishauser LK
J Manag Care Spec Pharm; 2014 Apr; 20(4):357-67. PubMed ID: 24684640
[TBL] [Abstract][Full Text] [Related]
17. Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study.
Joerger M; Schaer-Thuer C; Koeberle D; Matter-Walstra K; Gibbons-Marsico J; Diem S; Thuerlimann B; Cerny T
Eur J Clin Pharmacol; 2014 Jun; 70(6):719-25. PubMed ID: 24609468
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Duration of Response vs Conventional Response Rates and Progression-Free Survival as Efficacy End Points in Simulated Immuno-oncology Clinical Trials.
Hu C; Wang M; Wu C; Zhou H; Chen C; Diede S
JAMA Netw Open; 2021 May; 4(5):e218175. PubMed ID: 34047794
[TBL] [Abstract][Full Text] [Related]
19. Off-label prescriptions and decisions on reimbursement requests in Germany - a retrospective analysis.
Seidenschnur KEK; Dressler C; Weller K; Nast A; Werner RN
J Dtsch Dermatol Ges; 2017 Nov; 15(11):1103-1109. PubMed ID: 29064628
[TBL] [Abstract][Full Text] [Related]
20. Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials.
Chen EY; Joshi SK; Tran A; Prasad V
JAMA Intern Med; 2019 May; 179(5):642-647. PubMed ID: 30933235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
